FDA accepts immunotherapy drug for review in colon cancer treatment
DNA
Alliance for Clinical Trials in Oncology Jun 11 2026 The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq ® ) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by findings from the phase III Alliance
din zilele anterioare